title: [Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure].
abstract: We report 5 cases of colorectal liver metastases (CRLM) with hepatic arterial infusion (HAI) oxaliplatin after systemic infusion chemotherapy failure. Patients with unresectable CRLM and history of systemic chemotherapy failure were treated with HAI oxaliplatin (L-OHP 100 mg/body, 2 hours) combined with intravenous (iv) levofolinate calcium (175 mg/body, 2 hours) and iv bolus 5-FU (500 mg/body) every 2 weeks.
  
  
  RESULTS
  An average age was 58 years. All patients had previously received FOLFOX. Lung metastases had already existence before HAI oxaliplatin in 4 patients. A median of 10 treatments were administered (range 5-14). Serum level of CEA was decreased in 4 cases. In 2 patients, lung metastasis developed while a PR was obtained in the liver metastasis. Progress disease (PD) was confirmed in other 3 patients. No major toxicity was presented. The median time to progression free survival was 3.0 months and the median overall survival was 7.1 months.
  
  
  CONCLUSIONS
  HAI oxaliplatin might be beneficial as a salvage therapy for CRLM without extrahepatic metastasis, which demonstrated an acceptable tolerability and maintenance of QOL.
authors.affiliation: Division of General and Gastrointestinal Surgery, Dept of Surgery (Omori), Toho University School of Medicine.
authors.forename: Masaru
authors.initials: M
authors.lastname: Tsuchiya
authors.forename: Masashi
authors.initials: M
authors.lastname: Watanabe
authors.forename: Junichi
authors.initials: J
authors.lastname: Koike
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kubota
authors.forename: Takayuki
authors.initials: T
authors.lastname: Suzuki
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Otsuka
authors.forename: Akira
authors.initials: A
authors.lastname: Tamura
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Maeda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Shiokawa
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Arai
authors.forename: Akiharu
authors.initials: A
authors.lastname: Kurihara
authors.forename: Kimihiko
authors.initials: K
authors.lastname: Funahashi
authors.forename: Hideaki
authors.initials: H
authors.lastname: Shimada
authors.forename: Hironori
authors.initials: H
authors.lastname: Kaneko
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000473:pathology*; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007263:Infusions, Parenteral; D002955:Leucovorin / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000627:therapeutic use; D000077150:Oxaliplatin; D012189:Retrospective Studies; D016879:Salvage Therapy
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin